Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.

Panigrahy D, Gartung A, Yang J, Yang H, Gilligan MM, Sulciner ML, Bhasin SS, Bielenberg DR, Chang J, Schmidt BA, Piwowarski J, Fishbein A, Soler-Ferran D, Sparks MA, Staffa SJ, Sukhatme V, Hammock BD, Kieran MW, Huang S, Bhasin M, Serhan CN, Sukhatme VP.

J Clin Invest. 2019 Jun 17;129(7):2964-2979. doi: 10.1172/JCI127282. eCollection 2019 Jun 17.

2.

Repurposing Food and Drug Administration-Approved Drugs to Promote Antitumor Immunity.

Sukhatme VV, Ramalingam SS, Ahmed R, Sukhatme VP.

Cancer J. 2019 Mar/Apr;25(2):88-99. doi: 10.1097/PPO.0000000000000368.

PMID:
30896530
3.

Introduction: Repurposed Drugs: Teaching an Old Dog New Tricks.

Sukhatme VP.

Cancer J. 2019 Mar/Apr;25(2):81. doi: 10.1097/PPO.0000000000000367. No abstract available.

PMID:
30896528
4.

Aspirin-triggered proresolving mediators stimulate resolution in cancer.

Gilligan MM, Gartung A, Sulciner ML, Norris PC, Sukhatme VP, Bielenberg DR, Huang S, Kieran MW, Serhan CN, Panigrahy D.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6292-6297. doi: 10.1073/pnas.1804000116. Epub 2019 Mar 12.

PMID:
30862734
5.

ReDO_DB: the repurposing drugs in oncology database.

Pantziarka P, Verbaanderd C, Sukhatme V, Rica Capistrano I, Crispino S, Gyawali B, Rooman I, Van Nuffel AM, Meheus L, Sukhatme VP, Bouche G.

Ecancermedicalscience. 2018 Dec 6;12:886. doi: 10.3332/ecancer.2018.886. eCollection 2018.

6.

Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.

Gartung A, Yang J, Sukhatme VP, Bielenberg DR, Fernandes D, Chang J, Schmidt BA, Hwang SH, Zurakowski D, Huang S, Kieran MW, Hammock BD, Panigrahy D.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703. doi: 10.1073/pnas.1803999116. Epub 2019 Jan 15.

7.

Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin.

Chang J, Bhasin SS, Bielenberg DR, Sukhatme VP, Bhasin M, Huang S, Kieran MW, Panigrahy D.

FASEB J. 2019 Jan;33(1):114-125. doi: 10.1096/fj.201800019RR. Epub 2018 Jun 29.

8.

Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents.

Pantziarka P, Sukhatme V, Crispino S, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2018 Apr 11;12:824. doi: 10.3332/ecancer.2018.824. eCollection 2018.

9.

Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.

Verbaanderd C, Maes H, Schaaf MB, Sukhatme VP, Pantziarka P, Sukhatme V, Agostinis P, Bouche G.

Ecancermedicalscience. 2017 Nov 23;11:781. doi: 10.3332/ecancer.2017.781. eCollection 2017.

10.

Resolvins suppress tumor growth and enhance cancer therapy.

Sulciner ML, Serhan CN, Gilligan MM, Mudge DK, Chang J, Gartung A, Lehner KA, Bielenberg DR, Schmidt B, Dalli J, Greene ER, Gus-Brautbar Y, Piwowarski J, Mammoto T, Zurakowski D, Perretti M, Sukhatme VP, Kaipainen A, Kieran MW, Huang S, Panigrahy D.

J Exp Med. 2018 Jan 2;215(1):115-140. doi: 10.1084/jem.20170681. Epub 2017 Nov 30.

11.

Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway.

Ren JG, Seth P, Ye H, Guo K, Hanai JI, Husain Z, Sukhatme VP.

Sci Rep. 2017 Jul 3;7(1):4537. doi: 10.1038/s41598-017-04626-4.

12.

Adipose-derived aldehyde dehydrogenase-expressing cells promote dermal regenerative potential with collagen-glycosaminoglycan scaffold.

Matsumine H, Numakura K, Tsunoda S, Wang H, Matsumine R, Climov M, Giatsidis G, Sukhatme VP, Orgill DP.

Wound Repair Regen. 2017 Jan;25(1):109-119. doi: 10.1111/wrr.12494. Epub 2017 Feb 23.

PMID:
28230922
13.

Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening.

Jernigan FE, Hanai JI, Sukhatme VP, Sun L.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):929-935. doi: 10.1016/j.bmcl.2017.01.001. Epub 2017 Jan 16.

PMID:
28129980
14.

Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.

Koerner SK, Hanai JI, Bai S, Jernigan FE, Oki M, Komaba C, Shuto E, Sukhatme VP, Sun L.

Eur J Med Chem. 2017 Jan 27;126:920-928. doi: 10.1016/j.ejmech.2016.12.018. Epub 2016 Dec 9.

PMID:
27997879
15.

Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent.

Pantziarka P, Bouche G, Sukhatme V, Meheus L, Rooman I, Sukhatme VP.

Ecancermedicalscience. 2016 Oct 12;10:680. eCollection 2016.

16.

Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1α and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro.

Tanaka T, Ikegami Y, Nakazawa H, Kuriyama N, Oki M, Hanai J, Sukhatme VP, Kaneki M.

J Cell Physiol. 2017 Jan;232(1):192-201. doi: 10.1002/jcp.25411. Epub 2016 Jun 15.

PMID:
27137755
17.

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.

Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP, Kufe D.

Oncotarget. 2016 Mar 15;7(11):11756-69. doi: 10.18632/oncotarget.7598.

18.
19.

Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2016 Jan 11;10:610. doi: 10.3332/ecancer.2016.610. eCollection 2016.

20.

Selective spectroscopic imaging of hyperpolarized pyruvate and its metabolites using a single-echo variable phase advance method in balanced SSFP.

Varma G, Wang X, Vinogradov E, Bhatt RS, Sukhatme VP, Seth P, Lenkinski RE, Alsop DC, Grant AK.

Magn Reson Med. 2016 Oct;76(4):1102-15. doi: 10.1002/mrm.26004. Epub 2015 Oct 28.

21.

Drug repurposing in oncology--patient and health systems opportunities.

Bertolini F, Sukhatme VP, Bouche G.

Nat Rev Clin Oncol. 2015 Dec;12(12):732-42. doi: 10.1038/nrclinonc.2015.169. Epub 2015 Oct 20. Review.

PMID:
26483297
22.

Repurposing Drugs in Oncology (ReDO)-nitroglycerin as an anti-cancer agent.

Sukhatme V, Bouche G, Meheus L, Sukhatme VP, Pantziarka P.

Ecancermedicalscience. 2015 Aug 27;9:568. doi: 10.3332/ecancer.2015.568. eCollection 2015.

23.

Erratum to: Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2015 May 12;16:95. doi: 10.1186/s13059-015-0658-5.

24.

Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent.

Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP.

Ecancermedicalscience. 2015 Apr 15;9:521. doi: 10.3332/ecancer.2015.521. eCollection 2015.

25.

Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G.

Ecancermedicalscience. 2015 Feb 24;9:513. doi: 10.3332/ecancer.2015.513. eCollection 2015.

26.

Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP.

Future Oncol. 2015;11(2):181-4. doi: 10.2217/fon.14.244. No abstract available.

27.

Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP.

Ecancermedicalscience. 2014 Nov 26;8:485. doi: 10.3332/ecancer.2014.485. eCollection 2014.

28.

Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent.

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP.

Ecancermedicalscience. 2014 Jul 10;8:443. doi: 10.3332/ecancer.2014.443. eCollection 2014.

29.

The Repurposing Drugs in Oncology (ReDO) Project.

Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP, Vikas P.

Ecancermedicalscience. 2014 Jul 10;8:442. doi: 10.3332/ecancer.2014.442. eCollection 2014.

30.

Knockdown of malic enzyme 2 suppresses lung tumor growth, induces differentiation and impacts PI3K/AKT signaling.

Ren JG, Seth P, Clish CB, Lorkiewicz PK, Higashi RM, Lane AN, Fan TW, Sukhatme VP.

Sci Rep. 2014 Jun 24;4:5414. doi: 10.1038/srep05414.

31.

Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells.

Xie H, Hanai J, Ren JG, Kats L, Burgess K, Bhargava P, Signoretti S, Billiard J, Duffy KJ, Grant A, Wang X, Lorkiewicz PK, Schatzman S, Bousamra M 2nd, Lane AN, Higashi RM, Fan TW, Pandolfi PP, Sukhatme VP, Seth P.

Cell Metab. 2014 May 6;19(5):795-809. doi: 10.1016/j.cmet.2014.03.003. Epub 2014 Apr 10.

32.

Tumor-derived lactate and myeloid-derived suppressor cells: Linking metabolism to cancer immunology.

Husain Z, Seth P, Sukhatme VP.

Oncoimmunology. 2013 Nov 1;2(11):e26383. Epub 2013 Oct 9.

33.

Modeling precision treatment of breast cancer.

Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, van't Veer LJ, Spellman PT, Gray JW.

Genome Biol. 2013;14(10):R110. Erratum in: Genome Biol. 2015;16:95.

34.

Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.

Wegiel B, Gallo D, Csizmadia E, Harris C, Belcher J, Vercellotti GM, Penacho N, Seth P, Sukhatme V, Ahmed A, Pandolfi PP, Helczynski L, Bjartell A, Persson JL, Otterbein LE.

Cancer Res. 2013 Dec 1;73(23):7009-21. doi: 10.1158/0008-5472.CAN-13-1075. Epub 2013 Oct 11.

35.

One-step purification of soluble recombinant human 6-phosphogluconate dehydrogenase from Escherichia coli.

Chan B, Sukhatme VP.

Protein Expr Purif. 2013 Nov;92(1):62-6. doi: 10.1016/j.pep.2013.08.017. Epub 2013 Sep 7.

PMID:
24018234
36.

Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.

Retsky M, Demicheli R, Hrushesky WJ, Forget P, De Kock M, Gukas I, Rogers RA, Baum M, Sukhatme V, Vaidya JS.

Curr Med Chem. 2013;20(33):4163-76. Review.

37.

6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met.

Chan B, VanderLaan PA, Sukhatme VP.

Biochem Biophys Res Commun. 2013 Sep 20;439(2):247-51. doi: 10.1016/j.bbrc.2013.08.048. Epub 2013 Aug 22.

PMID:
23973484
38.

Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.

Husain Z, Huang Y, Seth P, Sukhatme VP.

J Immunol. 2013 Aug 1;191(3):1486-95. doi: 10.4049/jimmunol.1202702. Epub 2013 Jul 1.

39.

ATP citrate lyase knockdown impacts cancer stem cells in vitro.

Hanai JI, Doro N, Seth P, Sukhatme VP.

Cell Death Dis. 2013 Jun 27;4:e696. doi: 10.1038/cddis.2013.215.

40.

Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors.

Cerdeira AS, Rajakumar A, Royle CM, Lo A, Husain Z, Thadhani RI, Sukhatme VP, Karumanchi SA, Kopcow HD.

J Immunol. 2013 Apr 15;190(8):3939-48. doi: 10.4049/jimmunol.1202582. Epub 2013 Mar 13.

41.

Predicting the cost and pace of pharmacogenomic advances: an evidence-based study.

Arnaout R, Buck TP, Roulette P, Sukhatme VP.

Clin Chem. 2013 Apr;59(4):649-57. doi: 10.1373/clinchem.2012.199455. Epub 2013 Jan 4.

42.

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice.

Sun X, Han L, Seth P, Bian S, Li L, Csizmadia E, Junger WG, Schmelzle M, Usheva A, Tapper EB, Baffy G, Sukhatme VP, Wu Y, Robson SC.

Hepatology. 2013 Jan;57(1):205-16. doi: 10.1002/hep.25989.

43.

Glycolytic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence.

Sukhatme VP, Chan B.

FEBS Lett. 2012 Jul 30;586(16):2389-95. doi: 10.1016/j.febslet.2012.05.052. Epub 2012 Jun 4.

44.

A small-molecule screening strategy to identify suppressors of statin myopathy.

Wagner BK, Gilbert TJ, Hanai J, Imamura S, Bodycombe NE, Bon RS, Waldmann H, Clemons PA, Sukhatme VP, Mootha VK.

ACS Chem Biol. 2011 Sep 16;6(9):900-4. doi: 10.1021/cb200206w. Epub 2011 Jul 15.

45.
46.

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma.

Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV.

Br J Cancer. 2011 Jun 28;105(1):112-7. doi: 10.1038/bjc.2011.186. Epub 2011 Jun 14.

47.

On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvate.

Seth P, Grant A, Tang J, Vinogradov E, Wang X, Lenkinski R, Sukhatme VP.

Neoplasia. 2011 Jan;13(1):60-71.

48.

Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2.

Ren JG, Seth P, Everett P, Clish CB, Sukhatme VP.

PLoS One. 2010 Sep 2;5(9). pii: e12520. doi: 10.1371/journal.pone.0012520.

49.

A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.

Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP.

Cancer. 2010 Apr 1;116(7):1751-6. doi: 10.1002/cncr.24902.

50.

Drug discovery. Repurposing with a difference.

Boguski MS, Mandl KD, Sukhatme VP.

Science. 2009 Jun 12;324(5933):1394-5. doi: 10.1126/science.1169920. No abstract available.

PMID:
19520944

Supplemental Content

Loading ...
Support Center